Teva has also been granted 180-day exclusivity for a generic version of Janssen Pharmaceutical’s Risperdal (risperidone) tablets, which is used for the treatment of schizophrenia.
Teva expects final approval with exclusivity on June 29, 2008.
Teva has also been granted 180-day exclusivity for a generic version of Janssen Pharmaceutical’s Risperdal (risperidone) tablets, which is used for the treatment of schizophrenia.
Teva expects final approval with exclusivity on June 29, 2008.